Recent studies, using adriamycin-induced glomerulosclerosis animal models, suggested that IgM could activate the complement system within glomeruli, and strategies that reduct of IgM natural antibodies or prevent of complement activation could slow down the progression of glomerulosclerosis [8]. This evidence concerns the gene CD40LG and glomerulosclerosis.